RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Biocept , a San Diego liquid biopsy company, raised $2.2 million from Hong Kong’s Ally Bridge LB Healthcare Master Fund in a private placement. Biocept provides physicians with personal medicine tests for cancer treatment, using its Target Selector™ platform to analyze circulating tumor cells and circulating tumor DNA. In addition to the capital, Ally Bridge will help Biocept develop a strategic plan to bring its liquid biopsy platform to China.
Source: ChinaBio Today